April 28, 2020 - "Resilient business driving continued growth in challenging times"
MAY 11, 2020 – Today Orexo announces it has acquired the US rights to commercialize deprexis®, a world-leading digital therapy to manage depression. In the wake of the COVID-19 pandemic the need for digital therapies is unprecedented and the company will accelerate the US launch of its three therapies, also including vorvida® and OXD01, in 2020.
APRIL 28, 2020 – In Q1 a solid financial performance was reported, with both profitability and cash improving. The main driver was Zubsolv US with an EBIT margin of 46 percent. The impact of COVID-19 has been limited and the timelines for OX125 and OX124 is unchanged at this stage. In parallel the company is assessing to accelerate the launch of vorvida® and OXD01 in the US.
APRIL 16, 2020 – On May 19 Orexo will held an extraordinary general meeting at it´s headquarter in Uppsala, Sweden. Latest day for registration is May 13 and before attending in person please read our COVID-19 Visitation Policy. For access to all documents related to our EGM go to About US/Corporate Governance on our website and scroll down to the EGM section or press the link below.
MARCH 17, 2020 – On the Capital Markets Day today the company will present the sales potential for both the pharma projects and the digital therapies. Among others OX124 is expected to reach a sales potential of USD 70 m – USD 110 m in the US.
För dem som missade gårdagens sändning av Healthcare Direkt. "Orexos vd om köpet av USA-rättigheterna för deprexis"… https://t.co/WZn72DAm0G